Democratic presidential hopefuls for 2020 are targeting prescription drug prices; a US judge will hear arguments over California's attempt to block new Trump administration rules that would allow more categories of employers, including publicly traded companies, to opt out of providing no-cost birth control to women as required under the Affordable Care Act; Senate Democrats and Republicans are fighting over a proposed rule that would change how individuals are billed for abortion coverage, with both sides sending 2 letters to HHS this week.
Democratic presidential hopefuls for 2020 are targeting prescription drug prices, STAT News reported. The list includes Sen. Bernie Sanders, I-Vermont, who unveiled a proposal to lower drug prices that mirrors one from the administration. Sen. Cory Booker, D-New Jersey, and Sen. Elizabeth Warren, D-Massachusetts, have both amped up language about drug pricing. In addition, the House Oversight Committee has scheduled a hearing on the issue that will occur more than a week before it calls former Trump lawyer Michael Cohen to testify.A US judge will hear arguments over California's attempt to block new Trump administration rules that would allow more categories of employers, including publicly traded companies, to opt out of providing no-cost birth control to women as required under the Affordable Care Act. Reuters reported that Judge Haywood Gilliam previously blocked an interim version of those rules; his decision was upheld by an appeals court, but the case is before him again after the administration finalized the measures in November, prompting a renewed legal challenge by California and other states.Senate Democrats and Republicans are fighting over a proposed rule that would change how individuals are billed for abortion coverage, with both sides sending 2 letters to HHS this week, Roll Call reported. The proposal would require enrollees in Affordable Care Act plans to submit separate premiums for essential health benefits and for abortion coverage. The abortion fee would be required to be at least $1. The GOP wants the rule to move forward, while Democrats say it would impede access.
Elevated Inflammatory Marker Levels Associated With Increased Overactive Bladder Risk
April 15th 2025Systemic immune inflammation index, neutrophil-to-lymphocyte ratio, and systemic inflammation response index levels may offer a noninvasive method to identify individuals at increased risk of developing overactive bladder.
Read More
Personalized Care Key as Tirzepatide Use Expands Rapidly
April 15th 2025Using commercial insurance claims data and the US launch of tirzepatide as their dividing point, John Ostrominski, MD, Harvard Medical School, and his team studied trends in the use of both glucose-lowering and weight-lowering medications, comparing outcomes between adults with and without type 2 diabetes.
Listen
SGLT2 Inhibitors Show Renal Benefits in HF and CKD as Prescribers Target Uptake Gaps
April 15th 2025Abstracts featured at the National Kidney Foundation Spring Clinical Meeting highlighted the renoprotective benefits of SGLT2 inhibitors in heart failure and diabetic kidney disease while emphasizing the need for strategies to increase their uptake in primary care.
Read More